IKT News

Latest breaking news and updates for IKT stock.

Track all markets on TradingView

Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to m...

How does this executive addition compare to recent leadership moves at competing PAH biotech firms, and what could it mean for Inhibikase's competitive positioning? What immediate impact might this leadership change have on IKT's stock price, trading volume, and analyst sentiment? How will Timothy Pigot's appointment as Chief Commercial and Strategy Officer influence Inhibikase Therapeutics' commercial execution and revenue forecasts for its PAH pipeline?
Leadership
22 days ago
Read more globenewswire

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to m...

What macroeconomic or sector trends (e.g., interest rates, healthcare policy changes) might amplify or dampen the market reaction to this earnings release? Are there any regulatory or compliance updates—such as FDA filings or IND submissions—that could affect the timeline for product commercialization? How does the sentiment score of 30 align with analyst sentiment and market expectations for IKT, and could it signal a potential price swing?
Earnings
27 days ago
Read more globenewswire